PercAssist

Executive Summary

PercAssist is a preclinical-stage medical device company developing the PercAssist eVAD™ System, a novel extravascular ventricular assist device (VAD) that provides direct cardiac compression without requiring vascular access. This approach aims to reduce complications associated with traditional intravascular VADs, such as bleeding and infection. Founded in 2016 and headquartered in San Francisco, the company is progressing its technology through clinical studies, targeting mechanical circulatory support for patients with heart failure. While still in early development, PercAssist's differentiated design could address significant unmet needs in the VAD market. However, given the preclinical stage, the company faces typical risks related to clinical validation, regulatory approval, and funding.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Study40% success
• Q2 2027Series B or C Financing Round50% success
• Q3 2026FDA Breakthrough Device Designation60% success